Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

KRT14 Antikörper (C-Term) (CF®568)

Der Maus Monoklonal Anti-KRT14-Antikörper wurde für IF, FACS und IHC (f) validiert. Er ist geeignet, KRT14 in Proben von Human, Ratte und Maus zu detektieren.
Produktnummer ABIN6172564

Kurzübersicht für KRT14 Antikörper (C-Term) (CF®568) (ABIN6172564)

Target

Alle KRT14 Antikörper anzeigen
KRT14 (Keratin 14 (KRT14))

Reaktivität

  • 116
  • 74
  • 60
  • 16
  • 6
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
Human, Ratte, Maus

Wirt

  • 73
  • 49
  • 2
Maus

Klonalität

  • 63
  • 60
  • 1
Monoklonal

Konjugat

  • 72
  • 7
  • 6
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser KRT14 Antikörper ist konjugiert mit CF®568

Applikation

  • 52
  • 50
  • 40
  • 30
  • 26
  • 17
  • 15
  • 13
  • 13
  • 12
  • 11
  • 11
  • 10
  • 2
  • 2
  • 1
  • 1
Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Klon

LL002
  • Bindungsspezifität

    • 26
    • 15
    • 14
    • 9
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term

    Verwendungszweck

    Mouse Monoclonal anti-Cytokeratin 14 (LL002), CF568 Conjugate

    Produktmerkmale

    Cytokeratin 14 (CK14) belongs to the type I (or A or acidic) subfamily of low molecular weight keratins and exists in combination with keratin 5 (type II or B or basic). CK14 is found in basal cells of squamous epithelia, some glandular epithelia, myoepithelium, and mesothelial cells. Anti-CK14 is useful in differentiating squamous cell carcinomas from poorly differentiated epithelial tumors. Anti-CK14 is one of the specific basal markers for distinguishing between basal and non-basal subtypes of breast carcinomas. Anti-CK14 is also a good marker for differentiation of intraductal from invasive salivary duct carcinoma by the positive staining of basal cells surrounding the in-situ neoplasm as well as for differentiation of benign prostate from prostate carcinoma. Furthermore, this antibody has been useful in separating oncocytic tumors of the kidney from its renal mimics, and in identifying metaplastic carcinomas of the breast. Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

    Immunogen

    A synthetic peptide of 15 amino acid from the C-terminus of human keratin 14.

    Isotyp

    IgG3
  • Applikationshinweise

    Immunohistology formalin-fixed 0.5-1.0 μg/mL
    • Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes
    • Immunofluorescence 0.5-1 μg/mL
    • Flow Cytometry 0.5-1 μg/million cells/0.1 mL
    • Optimal dilution for a specific application should be determined by user

    Kommentare

    A431 cells. Skin or Squamous cell carcinoma

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    100 μg/mL

    Buffer

    PBS/0.1 % BSA/0.05 % azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Handhabung

    Protect from light
  • Target

    KRT14 (Keratin 14 (KRT14))

    Andere Bezeichnung

    Cytokeratin 14

    Hintergrund

    CK-14, Dowling Meara, ebs3, ebs4, Epidermolysis Bullosa Simplex, k14, Keratin 14, Keratin Type I Cytoskeletal 14, Koebner, krt14, NFJ

    Molekulargewicht

    ~50 kDa

    Gen-ID

    3861, 6545380

    UniProt

    P02533
Sie sind hier:
Chat with us!